Latest period
$1.27B
YoY change
-53.4%
5Y CAGR
+19.7%
Peak year (2024)
$2.74B
Latest annual
$1.28B
Total Debt history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $1.28B
Total Debt growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: -53.4%
Total Debt history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $1.28B | -53.4% | −$1.47B | ||
| 2024 | $2.74B | +110.2% | +$1.44B | ||
| 2023 | $1.31B | -1.1% | −$14.86M | ||
| 2022 | $1.32B | +32.3% | +$322.66M | ||
| 2021 | $997.59M | +91.4% | +$476.40M | ||
| 2020 | $521.19M | +71.5% | +$217.37M | ||
| 2019 | $303.82M | +912.7% | +$273.82M | ||
| 2018 | $30.00M | 0.0% | $0.00 | ||
| 2017 | $30.00M | -80.0% | −$120.00M | ||
| 2016 | $150.00M | — | +$150.00M | ||
| 2015 | $0.00 | — | $0.00 | ||
| 2014 | $0.00 | — | $0.00 | ||
| 2013 | $0.00 | — | $0.00 | ||
| 2012 | $0.00 | — | $0.00 | ||
| 2011 | $0.00 | — | $0.00 | ||
| 2010 | $0.00 | — | $0.00 | ||
| 2009 | $0.00 | — | $0.00 | ||
| 2008 | $0.00 | -100.0% | −$6.76M | ||
| 2007 | $6.76M | -26.0% | −$2.38M | ||
| 2006 | $9.14M | +23.5% | +$1.74M | ||
| 2005 | $7.39M | +2.7% | +$194.00K | ||
| 2004 | $7.20M | +287.4% | +$5.34M | ||
| 2003 | $1.86M | — | +$1.86M | ||
| 2002 | $0.00 | — | — |
- 2025$1.28B-53.4%
- 2024$2.74B+110.2%
- 2023$1.31B-1.1%
- 2022$1.32B+32.3%
- 2021$997.59M+91.4%
- 2020$521.19M+71.5%
- 2019$303.82M+912.7%
- 2018$30.00M0.0%
- 2017$30.00M-80.0%
- 2016$150.00M—
- 2015$0.00—
- 2014$0.00—
- 2013$0.00—
- 2012$0.00—
- 2011$0.00—
- 2010$0.00—
- 2009$0.00—
- 2008$0.00-100.0%
- 2007$6.76M-26.0%
- 2006$9.14M+23.5%
- 2005$7.39M+2.7%
- 2004$7.20M+287.4%
- 2003$1.86M—
- 2002$0.00—
Total Debt values are taken from Alnylam Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Debt at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported total debt is $1.27B. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — compare with cash on hand for net leverage, and total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Alnylam Pharmaceuticals (ALNY) total debt is $1.28B – plunged 53.4% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Alnylam Pharmaceuticals total debt compounded at +19.7% per year, with mixed annual results across the window.
The record annual total debt stands at $2.74B, reached in 2024; the historical low of $0.00 was recorded in 2002.
Alnylam Pharmaceuticals Total Debt by Year
Alnylam Pharmaceuticals Total Debt 2025: $1.28B
2025's total debt for Alnylam Pharmaceuticals came in at $1.28B, plunged 53.4% below 2024.
Alnylam Pharmaceuticals Total Debt 2024: $2.74B
Alnylam Pharmaceuticals posted total debt of $2.74B in 2024, surged 110.2% from 2023. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Total Debt 2023: $1.31B
In 2023, Alnylam Pharmaceuticals reported total debt of $1.31B, edged down 1.1% below 2022.
Alnylam Pharmaceuticals Total Debt 2022: $1.32B
Alnylam Pharmaceuticals total debt in 2022 was $1.32B, surged 32.3% from 2021.
Alnylam Pharmaceuticals Total Debt 2021: $997.59M
Alnylam Pharmaceuticals total debt in 2021 was $997.59M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Total Debt
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest total debt
| $78.39B | |
| $69.07B | |
| $54.60B | |
| $50.53B | |
| $47.93B | |
| $42.50B | |
| $29.70B | |
| $20.59B |
- $78.39B
- $69.07B
- $54.60B
- $50.53B
- $47.93B
- $42.50B
- $29.70B
- $20.59B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation